[Federal Register Volume 71, Number 37 (Friday, February 24, 2006)]
[Rules and Regulations]
[Pages 9458-9466]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 06-1711]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Parts 405, 410, 411, 413, 414, 424 and 426
[CMS-1502-F2 and CMS-1325-F]
RIN 0938-AN84 and 098-AN58
Medicare Program; Revisions to Payment Policies Under the
Physician Fee Schedule for Calendar Year 2006 and Certain Provisions
Related to the Competitive Acquisition Program of Outpatient Drugs and
Biologicals Under Part B; Correcting Amendment
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Correcting amendment to final rule with comment.
-----------------------------------------------------------------------
SUMMARY: In the November 21, 2005 Federal Register (70 FR 70116), we
published a final rule with comment period entitled ``Medicare Program;
Revisions to Payment Policies Under the Physician Fee Schedule for
Calendar Year 2006 and Certain Provisions Related to the Competitive
Acquisition Program of Outpatient Drugs and Biologicals Under Part B.''
This correcting amendment corrects technical errors in the November 21,
2005 publication.
EFFECTIVE DATE: This correcting amendment is effective January 1, 2006.
FOR FURTHER INFORMATION CONTACT: Diane Milstead, (410) 786-3355.
SUPPLEMENTARY INFORMATION:
I. Background
FR Doc. 05-22160, entitled ``Medicare Program; Revisions to Payment
Policies Under the Physician Fee Schedule for Calendar Year 2006 and
Certain Provisions Related to the Competitive Acquisition Program of
Outpatient Drugs and Biologicals Under Part B'' and appearing in the
Federal Register on November 21, 2005 (70 FR 70116), addressed Medicare
Part B payment policy, including the physician fee schedule, that is
applicable for calendar year (CY) 2006; and finalized certain
provisions of the interim final rule to implement the Competitive
Acquisition Program (CAP) for Part B Drugs.
It also revised Medicare Part B payment and related policies
regarding: Physician work, practice expense and malpractice relative
value units (RVUs); Medicare telehealth services; multiple diagnostic
imaging procedures; covered outpatient drugs and biologicals;
supplemental payments to Federally Qualified Health Centers (FQHCs);
renal dialysis services; coverage for glaucoma screening services;
National Coverage Decision (NCD) timeframes; and physician referrals
for nuclear medicine services and supplies to health care entities with
which physicians have financial relationships.
In addition, the rule finalized the interim RVUs for CY 2005 and
issued interim RVUs for new and revised procedure codes for CY 2006.
This rule also updated the codes subject to the physician self-referral
prohibition and discussed payment policies relating to teaching
anesthesia services, therapy caps, private contracts and opt-out, and
chiropractic and oncology demonstrations.
We have identified a number of technical errors in that final rule
with comment period.
II. Summary of Errors
We are identifying and correcting errors made to certain parts of
the preamble, regulations text and addenda of the November 21, 2005
final rule with comment (70 FR 70116). In addition, addendum B, C, D, E
and F are revised under this correcting amendment, although these
addenda will not appear in the Code of Federal Regulations.
A. Summary of Preamble Errors
In the preamble text, there were a number of errors and omissions
beginning on pages 70150 through 70335.
1. On page 70150, in the first column, in the last paragraph under
Section m. (Additional PE Issues Raised by Commenters), in the second
sentence, the number of the CPT code referenced is incorrect.
2. On page 70155, in the center column, the last sentence of the
second paragraph under the discussion titled, ``3. Cardiac
Catheritization and Angioplasty Exception,'' there was an error in one
of the code ranges referenced.
3. On page 70263, in the third column; in last paragraph, the
reference to Table 26 is incorrect.
4. On page 70263, Table 26 was numbered incorrectly.
5. On page 70274, in the first column; in the second paragraph
language concerning the specific deleted practice
[[Page 9459]]
expense items was inadvertently omitted.
6. On page 70282, in the second column; from the top of the column,
lines 8 through 11, the sentence, ``We are assigning a status indicator
of N for these services because they are nonvcovered under Medicare.''
reflects an incorrect status indicator and will be revised.
7. On page 70282, in the third column; we inadvertently omitted a
paragraph before section F. (Establishment of Interim PE RVUs for New
and Revised Physician's Current Procedural Terminology (CPT) Codes and
New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006).
8. On page 70296, in the second column; in the last paragraph, in
line 6, we incorrectly used the term ``PFS'', and that term will be
replaced.
9. On page 70302, in Table 35, the figures for Annual Actual
Expenditures and the Cumulative Actual Expenditures, for the period of
1/1/03-12/31/03, are incorrect and will be revised.
10. On page 70316, the first column, the percentage adjustment
referenced in the third complete sentence is incorrect and will be
revised.
11. On page 70320, the second footnote to Table 49 has incorrectly
listed the numerical scaler. This footnote will be corrected.
These corrections are reflected in Section III.A of this correcting
amendment.
B. Summary of Regulations Text Errors
In the regulation text, there were technical errors and omissions
in Sec. 405.2469, Sec. 414.190, Sec. 414.904, Sec. 414.906, and
Sec. 426.340.
1. On page 70329, in the third column, under Sec. 405.2469,
paragraph (a)(1) does not reflect the correct format for amendatory
language. Paragraph (a)(1) will be restructured.
2. On page 70331, in the third column, the reference to Sec.
414.190 is incorrect.
3. On page 70332, in the third column, the title (Basis for
payment.) for Sec. 414.904 is incorrect.
4. On page 70333, in the first column, under Sec. 414.906, we
inadvertently omitted a change to bring the regulations text into
conformity with our policy on updating CAP drug prices, as described in
the interim final rule with comment period published July 6, 2005.
5. On page 70335, in the first column, under Sec. 426.340, the
statutory references in paragraphs (e)(2)(ii) and (f)(2)(ii) are
incorrect.
The corrections are reflected in section III.B. of this correcting
amendment.
C. Summary of Addendum B, C, D, E and F Errors
1. In Addendum B, pages 70337 through 70463, we are making the
following corrections:
a. We assigned incorrect RVUs to the following Physicians' CPT or
HCPCS codes:
50000:
i. 52648;
60000:
ii. 61630, 61635;
80000:
iii. 88385-26, 88385-TC, 88385, 88386-26, 88386-TC, and 88386;
90000:
iv. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774,
90775, 92626, 92627, 93514, 96401, 96402, 96405, 96406, 96409, 96411,
96413, 96415, 96416, 96417, 96420, 96440, 96450, 96521, 96522, 96542,
97606, 99300, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336,
and 99337.
b. We assigned an incorrect global period for CPT code 92627.
c. We assigned incorrect status indicators to the following CPT or
codes 0141T, 0142T, 0143T, 88385-26, 88385-TC, 88385, 88386-26, 88386-
TC, 88386, 96523, 98960, 98961, 98962 and 99340.
d. The following HCPCS codes were inadvertently included: G9041,
G9042, G9043 and G9044. These numbers should not have been included
because they were not in effect.
e. HCPCS code G0332 was inadvertently omitted from the addendum.
f. The first footnote to addendum B should be corrected to read
``\1\CPT codes and descriptions only. Copyright 2005 American Medical
Association. All Rights Reserved. Applicable FARS/DFARS apply.''
These corrections are reflected in Sections III.C.1. and 2. of this
correcting amendment.
2. In Addendum C, pages 70463 through 70466, we are making the
following corrections:
a. We assigned incorrect RVUs to the following CPT or alphanumeric
HCPCS number for service codes:
60000:
i. 61630 and 61635.
80000:
ii. 88385-26 and 88386-26.
90000:
iii. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774,
90775, 92626, 92627, 96401, 96402, 96409, 96411, 96413, 96415, 96416,
96417, 96450, 96521, 96522, 96523, 96542, 99300, 99324, 99325, 99326,
99327, 99328, 99334, 99335, 99336 and 99337.
b. We assigned incorrect status indicators to the following CPT
codes 88385-26, 88386-26, 98960, 98961, 98962 and 99340.
These corrections are reflected in Section III.C.3 of this
correcting amendment.
3. In Addendum D, pages 70466 through 70467, we are correcting the
locality name ``Kansas*'' to read ``Kansas''.
These corrections are reflected in Section III.C.4 of this
correcting amendment.
4. In Addendum E, pages 70468 through 70469, we are correcting the
locality name ``Kansas*'' to read ``Kansas''.
These corrections are reflected in Section III.C.5 of this
correcting amendment.
5. In Addendum F, pages 70469 through 70471, we are correcting this
Addendum by replacing this Addendum in its entirety to address two
errors. First, we inadvertently left a discontinued HCPCS code, J1750,
on Addendum F. This code was replaced by J1751 and J1752 which are
found on Addendum G ``Revised New Drugs for CAP Bidding for 2006''.
Second, we included a new HCPCS code, J7318, which we understood would
replace HCPCS codes J7317 and J7320. HCPCS J7318 was not issued and
HCPCS codes J7317 & J3120 were retained. We have reweighted and
corrected Addendum F to reflect these changes.
These corrections are reflected in Section III.C.6 of this
correcting amendment.
III. Correction of Errors
In FR Doc. 05-22160, entitled ``Medicare Program; Revisions to
Payment Policies Under the Physician Fee Schedule for Calendar Year
2006 and Certain Provisions Related to the Competitive Acquisition
Program of Outpatient Drugs and Biologicals Under Part B,'' which
appeared in the Federal Register on November 21, 2005 (70 FR 70116),
make the following corrections:
A. Correction of Preamble Errors
1. On page 70150, in the first column; in the last paragraph under
Section m. (Additional PE Issues Raised by Commenters), in the second
sentence, the number ``99755'' is corrected to read ``97755''.
2. On page 70155, in the center column; the last sentence of the
second paragraph under the discussion titled, ``3. Cardiac
Catheterization and
[[Page 9460]]
Angioplasty Exception,'' the number ``93617'' is corrected to read
``93618''.
3. On page 70263, in the third column; in the last paragraph, the
phrase ``Table 26'' is corrected to read ``Table 26A''.
4. On page 70263, the table heading ``Table 26.--Example of
Payments'' is corrected to read ``Table 26A.--Example of Payments''.
5. On page 70274, in the first column; in the second paragraph, the
paragraph is corrected by adding a new sentence at the end of the
paragraph to read as follows: ``Because payment for the supplies and
equipment for both of these procedures is provided under a separate
DMERC policy, we have deleted the following practice expense items from
these codes: Supplies deleted include dressings, both Adaptic and
microporous, the drainage canister, and the sharp debridement kit--
which was identified as not being needed for the typical scenario; and,
the vacuum pump was deleted from the equipment.''
6. On page 70282, in the second column; lines 8 through 11, the
sentence, ``We are assigning a status indicator of N for these services
because they are noncovered under Medicare.'' is corrected to read,
``We are assigning a status indicator of B for these services because
payment for these services is bundled into payment for other Medicare
services.''
7. On page 70282, in the third column; we are adding a new
paragraph before section F. (Establishment of Interim PE RVUs for New
and Revised Physician's Current Procedural Terminology (CPT) Codes and
New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006).
The new paragraph reads as follows: ``CPT code 99339 Individual
physician supervision of patient (patient not present) in home,
domiciliary or rest home (e.g., assisted living facility) requiring
complex and multidisciplinary care modalities involving regular
physician development and/or revision of care plans, review of
subsequent reports of patient status, review of related laboratory and
other studies, communication (including telephone calls) for purposes
of assessment care decisions with health care professional(s), family
member(s), surrogate decision maker(s) (e.g., legal guardian) and/or
key caregiver(s) involved in patient's care, integration of new
information into the medical treatment plan and/or adjustment of
medical therapy, within a calendar month; 15-29 minutes.
CPT code 99340 Individual physician supervision of patient (patient
not present) in home, domiciliary or rest home (e.g., assisted living
facility) requiring complex and multidisciplinary care modalities
involving regular physician development and/or revision of care plans,
review of subsequent reports of patient status, review of related
laboratory and other studies, communication (including telephone calls)
for purposes of assessment care decisions with health care
professional(s), family member(s), surrogate decision maker(s) (e.g.,
legal guardian) and/or key caregiver(s) involved inpatient's care,
integration of new information into the medical treatment plan and/or
adjustment of medical therapy, within a calendar month; 30 minutes or
more. We are assigning a status indicator of B for these codes because
payment for these services is bundled into payment for other
services.''
8. On page 70296, in the second column; in the last paragraph, in
line 6, the term ``PFS'' is corrected to read ``Code List''.
9. On page 70302, in Table 35; in the third column titled ``Annual
Actual Expenditures'', in line 10 (1/1/03-12/31/03) of that column,
``76.8'' is corrected to read ``78.2''; and in the fifth column titled
``Cumulative Actual Expenditures'', in line 10 (1/1/03-12/31/03) of
that column, ``460.6'' is corrected to read ``462.0''.
10. On page 70316, in the first column; in the third complete
sentence, the figure ``-0.6'' is corrected to read ``-0.15''.
11. On page 70320, in the second footnote to Table 49, the figure
``0.9984'' is corrected to read ``0.9985''.
B. Correction of Regulation Text Errors
List of Subjects
42 CFR Part 405
Administrative practice and procedure, Health facilities, Health
professions, Kidney diseases, Medical devices, Medicare, Reporting and
recordkeeping requirements, Rural areas, X-rays.
42 CFR Part 414
Administrative practice and procedure, Health facilities, Health
professions, Kidney diseases, Medicare, Reporting and recordkeeping
requirements.
42 CFR Part 426
Administrative practice and procedure, Medicare, Reporting and
recordkeeping requirements.
Given the errors summarized in section II.B. of this correcting
amendment, we are making the following correcting amendments to 42 CFR
parts 405, 414, and 426:
PART 405--FEDERAL HEALTH INSURANCE FOR THE AGED AND DISABLED
0
1. The authority citation for part 405 continues to read as follows:
Authority: Secs. 1102, 1861, 1862(a), 1871, 1874, 1881, and
1886(k) of the Social Security Act (42 U.S.C. 1302, 1395x, 1395y(a),
1395hh, 1395kk, 1395rr, and 1395ww(k)), and sec. 353 of the Public
Health Service Act (42 U.S.C. 263a).
0
2. Section 405.2469 is amended by revising paragraph (a)(1) to read as
follows:
Sec. 405.2469 Federally Qualified Health Centers supplemental
payments.
* * * * *
(a) Calculation of supplemental payment. (1) The supplemental
payment for Federally Qualified Health Center covered services provided
to Medicare patients enrolled in Medicare Advantage plans is based on
the difference between--
(i) Payments received by the center from the Medicare Advantage
plan as determined on a per visit basis; and
(ii) The Federally Qualified Health Center's all-inclusive cost-
based per visit rate as set forth in this subpart, less any amount the
FQHC may charge as described in section 1857(e)(3)(B) of the Act.
* * * * *
PART 414--PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES
0
3. The authority citation for part 414 continues to read as follows:
Authority: Secs. 1102, 1871, and 1881(b)(1) of the Social
Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1)).
0
4. Section 414.906 is amended by revising paragraph (c)(1) introductory
text to read as follows:
Sec. 414.906 Competitive acquisition program as the basis of payment.
* * * * *
(c) Computation of payment amount. (1) Except as specified in
paragraph (c)(2) of this section, payment for CAP drugs is based on
bids submitted, as a result of the bidding process as described in
Sec. 414.910. Based on these bids, a single payment amount for each
CAP drug in the competitive acquisition area is determined on the basis
of the bids submitted and accepted and updated from the bidding period
to the payment year. This single payment amount is then updated on an
annual
[[Page 9461]]
basis based on the approved CAP vendor's reasonable net acquisition
costs for that category as determined by CMS, based, in part, on
information disclosed to CMS and limited by the weighted payment amount
established under section 1847A of the Act across all drugs for which a
composite bid is required in the category, and limited by the payment
amount established under section 1847A of the Act for each other drug
for which the approved CAP vendor submits a bid in accordance with
Sec. 414.910. Adjustment to the payment amounts may be made more often
than annually, but no more often than quarterly, in any of the
following cases:
* * * * *
PART 426--REVIEW OF NATIONAL COVERAGE DETERMINATIONS AND LOCAL
COVERAGE DETERMINATIONS
0
5. The authority citation for part 426 continues to read as follows:
Authority: Secs. 1102 and 1871 of the Social Security Act (42
U.S.C. 1302 and 1395hh).
0
6. Section 426.340 is amended by revising paragraphs (e)(2)(ii) and
(f)(2)(ii) to read as follows:
Sec. 426.340 Procedures for review of new evidence.
* * * * *
(e) * * *
(2) * * *
(ii) For NCDs, in compliance with the timeframes specified in
section 1862(1) of the Act, by which CMS completes the reconsideration.
(f) * * *
(2) * * *
(ii) For NCDs, the reconsideration timeframe specified by the
Board, in compliance with section 1862(l) of the Act.
* * * * *
C. Correction of Addendum Errors
0
Given the errors summarized in Section II.C of this correcting
amendment, we are making the following corrections to Addendum B, C, D,
E, and F. These addenda will not appear in the Code of Federal
Regulations.
0
1. On pages 70337 through 70463, the following entries to Addendum B
are corrected to read as follows:
Addendum B.--Relative Value Units (RVUs) and Related Information--Continued
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Physician Nonfacility Facility PE Malpractice Nonfacility Facility
CPT 1/HCPCS 2 Mod Status Description work RVUs 3 PE RVUs RVUs RVUs total total Global
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
0141T................................. ..... I................ Perq islet transplant........ 0.00 0.00 0.00 0.00 0.00 0.00 XXX
0142T................................. ..... I................ Open islet transplant........ 0.00 0.00 0.00 0.00 0.00 0.00 XXX
0143T................................. ..... I................ Laparoscopic islet transplant 0.00 0.00 0.00 0.00 0.00 0.00 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
52648................................. ..... A................ Laser surgery of prostate.... 11.19 74.15 4.80 0.79 86.07 16.78 090
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
61630................................. ..... N................ Intracranial angioplasty..... +21.08 NA 12.53 2.01 NA 35.62 090
61635................................. ..... N................ Intracran angioplasty w/stent +23.08 NA 13.58 2.20 NA 38.86 090
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
88385................................. 26 A................ Eval molecul probes, 51-250.. 1.50 0.65 NA 0.06 2.21 NA XXX
88385................................. TC A................ Eval molecul probes, 51-250.. 0.00 6.45 NA 0.06 6.51 NA XXX
88385................................. ..... A................ Eval molecul probes, 51-250.. 1.50 7.10 NA 0.12 8.72 NA XXX
88386................................. 26 A................ Eval molecul probes, 251-500. 1.88 0.82 NA 0.08 2.78 NA XXX
88386................................. TC A................ Eval molecul probes, 251-500. 0.00 6.23 NA 0.08 6.31 NA XXX
88386................................. ..... A................ Eval molecul probes, 251-500. 1.88 7.05 NA 0.16 9.09 NA XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
90760................................. ..... A................ Hydration iv infusion init... 0.17 1.43 NA 0.07 1.67 NA XXX
90761................................. ..... A................ Hydrate iv infusion, add-on.. 0.09 0.40 NA 0.04 0.53 NA ZZZ
90765................................. ..... A................ Ther/proph/diag iv inf, init. 0.2 11.76 NA 0.07 2.04 NA XXX
90766................................. ..... A................ Ther/proph/dg iv inf, add-on. 0.18 0.46 NA 0.04 0.68 NA ZZZ
90767................................. ..... A................ Tx/proph/dg addl seq iv inf.. 0.19 0.89 NA 0.04 1.12 NA ZZZ
90768................................. ..... A................ Ther/diag concurrent inf..... 0.17 0.44 NA 0.04 0.65 NA ZZZ
90772................................. ..... A................ Ther/proph/diag inj, sc/im... 0.17 0.31 NA 0.01 0.49 NA XXX
90773................................. ..... A................ Ther/proph/diag inj, ia...... 0.17 0.31 NA 0.02 0.50 NA XXX
90774................................. ..... A................ Ther/proph/diag inj, iv push. 0.18 1.30 NA 0.04 1.52 NA XXX
90775................................. ..... A................ Ther/proph/diag inj add-on... 0.10 0.57 NA 0.04 0.71 NA ZZZ
92626................................. ..... A................ Eval aud status rehab........ 0.00 2.20 NA 0.06 2.26 NA XXX
92627................................. ..... A................ Evallaud status rehab add-on. 0.00 0.55 NA .02 0.57 NA ZZZ
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
93514................................. ..... C................ Left heart catheterization... 0.00 0.00 0.00 0.00 0.00 0.00 000
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
96401................................. ..... A................ Chemo, anti-neopl, sq/im..... 0.2 11.17 NA 0.01 1.39 NA XXX
96402................................. ..... A................ Chemo hormon antineopl sq/im. 0.19 1.01 NA 0.01 1.21 NA XXX
96405................................. ..... A................ Chemo intralesional, up to 7. 0.52 2.44 0.24 0.03 2.99 0.79 000
96406................................. ..... A................ Chemo intralesional over 7... 0.80 3.02 0.29 0.03 3.85 1.12 000
96409................................. ..... A................ Chemo, iv push, sngl drug.... 0.24 2.93 NA 0.06 3.23 NA XXX
96411................................. ..... A................ Chemo, iv push, addl drug.... 0.20 1.61 NA 0.06 1.87 NA ZZZ
96413................................. ..... A................ Chemo, iv infusion, 1 hr..... 0.28 4.20 NA 0.08 4.56 NA XXX
96415................................. ..... A................ Chemo, iv infusion, addl hr.. 0.19 0.77 NA 0.07 1.03 NA ZZZ
96416................................. ..... A................ Chemo prolong infuse w/pump.. 0.21 4.61 NA 0.08 4.90 NA XXX
96417................................. ..... A................ Chemo iv infuse each addl seq 0.2 11.95 NA 0.07 2.23 NA ZZZ
96420................................. ..... A................ Chemo, ia, push technique.... 0.17 2.67 NA 0.08 2.92 NA XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
96440................................. ..... A................ Chemotherapy, intracavitary.. 2.37 8.15 1.23 0.17 10.693.77 000
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
96450................................. ..... A................ Chemotherapy, into CNS....... 1.53 6.97 1.29 0.09 8.59 2.91 000
96521................................. ..... A................ Refill/maint, portable pump.. 0.21 3.77 NA 0.06 4.04 NA XXX
96522................................. ..... A................ Refill/maint pump/resvr syst. 0.21 2.65 NA 0.06 2.92 NA XXX
96523................................. ..... A................ Irrig drug delivery device... 0.04 0.69 NA 0.01 0.74 NA XXX
96542................................. ..... A................ Chemotherapy injection....... 0.75 4.26 0.66 0.07 5.08 1.48 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
97606................................. ..... A................ Neg press wound tx, >50 cm... 0.60 0.35 0.24 0.03 0.98 0.87 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
[[Page 9462]]
Addendum B.--Relative Value Units (RVUs) and Related Information--Continued
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Physician Nonfacility Facility PE Malpractice Nonfacility Facility
CPT 1/HCPCS 2 Mod Status Description work RVUs 3 PE RVUs RVUs RVUs total total Global
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
98960................................. ..... B................ Self-mgmt educ & train, 1 pt. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
98961................................. ..... B................ Self-mgmt educ/train, 2-4 pt. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
98962................................. ..... B................ Self-mgmt educ/train, 5-8 pt. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
99300................................. ..... A................ lc, infant pbw 2501-5000 gm.. 2.40 NA 0.84 0.15 NA 3.35 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
99324................................. ..... A................ Domicil/r-home visit new pat. 1.01 0.49 NA 0.05 1.55 NA XXX
99325................................. ..... A................ Domicil/r-home visit new pat. 1.52 0.68 NA 0.07 2.27 NA XXX
99326................................. ..... A................ Domicil/r-home visit new pat. 2.27 0.92 NA 0.10 3.29 NA XXX
99327................................. ..... A................ Domicil/r-home visit new pat. 3.03 1.17 NA 0.13 4.33 NA XXX
99328................................. ..... A................ Domicil/r-home visit new pat. 3.78 1.42 NA 0.16 5.36 NA XXX
99334................................. ..... A................ Domicil/r-home visit est pat. 0.76 0.40 NA 0.04 1.20 NA XXX
99335................................. ..... A................ Domicil/r-home visit est pat. 1.26 0.58 NA 0.06 1.90 NA XXX
99336................................. ..... A................ Domicil/r-home visit est pat. 2.02 0.82 NA 0.09 2.93 NA XXX
99337................................. ..... A................ Domicil/r-home visit est pat. 3.03 1.15 NA 0.13 4.31 NA XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
99340................................. ..... B................ Domicil/r-home care supervis. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
G0332................................. ..... A................ Preadmin IV immunoglobulin... 0.00 1.91 NA 0.00 1.91 NA XXX
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
\2\ Copyright 2005 American Dental Association. All Rights Reserved.
\3\ Indicates RVUs are not used for Medicare payment.
2. On page 70463, the following entries to Addendum B, G9041,
G9042, G9043, and G9044 are removed.
Addendum B.--Relative Value Units (RVUs) and Related Information--Continued
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Physician
CPT \1\/HCPCS \2\ Mod Status Description work RVUs Nonfacility Facility PE Malpractice Nonfacility Facility Global
\3\ PE RVUs RVUs RVUs total total
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
G9041................................. ..... X................ Low vision rehab occupationa. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
G9042................................. ..... X................ Low vision rehab orient/mobi. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
G9043................................. ..... X................ Low vision lowvision therapy. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
G9044................................. ..... X................ Low vision rehabilate teache. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
\2\ Copyright 2005 American Dental Association. All Rights Reserved.
\3\ +Indicates RVUs are not used for Medicare payment.
0
3. On pages 70463 through 70466, the following entries to Addendum C
are corrected to read as follows:
Addendum C.--Codes With Interim RVUs
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Physician
CPT \1\/ HCPCS \2\ Mod Status Description work RVUs Nonfacility Facility PE Malpractice Nonfacility Facility Global
\3\ PE RVUs RVUs RVUs Total Total
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
61630................................. ..... N................ Intracranial angioplasty..... +21.08 NA 12.53 2.01 NA 35.62 090
61635................................. ..... N................ Intracran angioplasty w/stent +23.08 NA 13.58 2.20 NA 30.66 090
88385................................. 26 A................ Eval Molecul probes, 51-250.. 1.50 0.65 NA 0.06 2.21 NA XXX
88386................................. 26 A................ Eval Molecul probes, 251-500. 1.88 0.82 NA 0.08 2.78 NA XXX
90760................................. ..... A................ Hydration iv infusion, init.. 0.17 1.43 NA 0.07 1.67 NA XXX
90761................................. ..... A................ Hydrate iv infusion, add-on.. 0.09 0.40 NA 0.04 0.53 NA ZZZ
90765................................. ..... A................ Ther/proph/diag iv inf, init. 0.21 1.76 NA 0.07 2.04 NA XXX
90766................................. ..... A................ Ther/proph/dg iv inf, add-on. 0.18 0.46 NA 0.04 0.68 NA ZZZ
90767................................. ..... A................ Tx/proph/dg addl seq iv inf.. 0.19 0.89 NA 0.04 1.12 NA ZZZ
90768................................. ..... A................ Ther/diag concurrent inf..... 0.17 0.44 NA 0.04 0.65 NA ZZZ
90772................................. ..... A................ Ther/proph/diag inj, sc/im... 0.17 0.31 NA 0.01 0.49 NA XXX
90773................................. ..... A................ Ther/proph/diag inj, ia...... 0.17 0.31 NA 0.02 0.50 NA XXX
90774................................. ..... A................ Ther/proph/diag inj, iv push. 0.18 1.30 NA 0.04 1.52 NA XXX
90775................................. ..... A................ Ther/proph/diag inj add-on... 0.10 0.57 NA 0.04 0.71 NA ZZZ
92626................................. ..... A................ Eval aud status rehab........ 0.00 2.20 NA 0.06 2.26 NA XXX
92627................................. ..... A................ Evalaud status rehab add-on.. 0.00 0.55 NA 0.02 0.57 NA ZZZ
96401................................. ..... A................ Chemo, anti-neopl, sq/im..... 0.21 1.17 NA 0.01 1.39 NA XXX
96402................................. ..... A................ Chemo hormone antineopl sq/im 0.19 1.01 NA 0.01 1.21 NA XXX
96409................................. ..... A................ Chemo, iv push, sngl drug.... 0.24 2.93 NA 0.06 3.23 NA XXX
96411................................. ..... A................ Chemo, iv push, addl drug.... 0.20 1.61 NA 0.06 1.87 NA ZZZ
96413................................. ..... A................ Chemo, iv infusion, 1 hr..... 0.28 4.20 NA 0.08 4.56 NA XXX
96415................................. ..... A................ Chemo, iv infusion, addl hr.. 0.19 0.77 NA 0.07 1.03 NA ZZZ
96416................................. ..... A................ Chemo prolong infuse w/pump.. 0.21 4.61 NA 0.08 4.90 NA XXX
96417................................. ..... A................ Chemo iv infuse each addl seq 0.21 1.95 NA 0.07 2.23 NA ZZZ
96450................................. ..... A................ Chemotherapy, into CNS....... 1.53 6.97 1.29 0.09 8.59 2.91 000
[[Page 9463]]
96521................................. ..... A................ Refill/maint, portable pump.. 0.21 3.77 NA 0.06 4.04 NA XXX
96522................................. ..... A................ Refil/maint pump/resvr syst.. 0.21 2.65 NA 0.06 2.92 NA XXX
96523................................. ..... A................ Irrig drug delivery device... 0.04 0.69 NA 0.01 0.74 NA XXX
96542................................. ..... A................ Chemotherapy injection....... 0.75 4.26 0.66 0.07 5.08 1.48 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
98960................................. ..... B................ Self-mgmt educ & train, 1 pt. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
98961................................. ..... B................ Self-mgmt educ/train, 2-4 pt. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
98962................................. ..... B................ Self-mgmt educ/train 5-8 pt.. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
99300................................. ..... A................ Ic, infant pbw 2501-5000 gm.. 2.40 NA 0.84 0.15 NA 3.35 XXX
99324................................. ..... A................ Domicil/r-home visit new pat. 1.01 0.49 NA 0.05 1.55 NA XXX
99325................................. ..... A................ Domicil/r-home visit new pat. 1.52 0.68 NA 0.07 2.27 NA XXX
99326................................. ..... A................ Domicil/r-home visit new pat. 2.27 0.92 NA 0.10 3.29 NA XXX
99327................................. ..... A............... Domicil/r-home visit new pat. 3.03 1.17 NA 0.13 4.33 NA XXX
99328................................. ..... A................ Domicil/r-home visit new pat. 3.78 1.42 NA 0.16 5.36 NA XXX
99334................................. ..... A................ Domicil/r-home visit est pat. 0.76 0.40 NA 0.04 1.20 NA XXX
99335................................. ..... A................ Domicil/r-home visit est pat. 1.26 0.58 NA 0.06 1.90 NA XXX
99336................................. ..... A................ Domicil/r-home visit est pat. 2.02 0.82 NA 0.09 2.93 NA XXX
99337................................. ..... A................ Domicil/r-home visit est pat. 3.03 1.15 NA 0.13 4.31 NA XXX
..... ................. ............................. ........... ........... ........... ........... ........... ........... .................
99340................................. ..... B................ Domicil/r-home care supervis. 0.00 0.00 0.00 0.00 0.00 0.00 XXX
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
\2\ Copyright 2005 American Dental Association. All Rights Reserved.
\3\ +Indicates RVUs are not used for Medicare payment.
0
4. On page 70467, in Addendum D, in the 11th entry, in the third
column, the locality ``Kansas*'' is corrected to read ``Kansas'' as
follows:
Addendum D.--2006 Geographic Practice Cost Indices by Medicare Carrier and Locality--Continued
----------------------------------------------------------------------------------------------------------------
Carrier Locality Locality name Work GPCI PE GPCI MP GPCI
----------------------------------------------------------------------------------------------------------------
00650............................... 00 Kansas................ 1.000 0.878 0.721
----------------------------------------------------------------------------------------------------------------
0
5. On page 70469, in Addendum E, in the fourth entry, in the third
column, the locality ``Kansas*'' is corrected to read ``Kansas'' as
follows:
Addendum E.--2006 GAFs--Continued
------------------------------------------------------------------------
Carrier Locality Locality name 2006 GAF
------------------------------------------------------------------------
00650........................ 00 Kansas......... 0.0936
------------------------------------------------------------------------
0
6. On pages 70469 through 70471, Addendum F, in its entirety, is
corrected to read as follows:
Addendum F.--Revised Single Drug Category List
------------------------------------------------------------------------
HCPCS Long description Weight
------------------------------------------------------------------------
J0150.......................... Injection, adenosine 0.00070000
for therapeutic use, 6
mg.
J0152.......................... Injection, adenosine 0.00459478
for diagnostic use, 30
mg.
J0170.......................... Injection, adrenalin, 0.00007897
epinephrine, 1 ml
ampule.
J0207.......................... Injection, amifostine, 0.00016099
500 mg.
J0215.......................... Injection, alefacept, 0.00083383
0.5 mg.
J0280.......................... Injection, 0.00082088
aminophyllin, 250 mg.
J0290.......................... Injection, ampicillin 0.00012657
sodium, 500 mg.
J0475.......................... Injection, baclofen, 10 0.00024643
mg.
J0540.......................... Injection, penicillin g 0.00007209
benzathine and
penicillin g procaine,
1,200,000 units.
J0550.......................... Injection, penicillin g 0.00001831
benzathine and
penicillin g procaine,
2,400,000 units.
J0570.......................... Injection, penicillin g 0.00004605
benzathine, 1,200,000
units.
J0585.......................... Botulinum toxin type A, 0.03743206
per unit.
J0587.......................... Botulinum toxin type B, 0.00150704
per 100 units.
J0600.......................... Injection, edetate 0.00004459
calcium disodium, 1000
mg.
J0637.......................... Injection, caspofungin 0.00008483
acetate, 5 mg.
J0640.......................... Injection, leucovorin 0.01064503
calcium, per 50 mg.
J0670.......................... Injection, mepivacaine 0.00038398
hydrochloride, per 10
ml.
[[Page 9464]]
J0690.......................... Injection, cefazolin 0.00042410
sodium, 500 mg.
J0692.......................... Injection, cefepime 0.00024846
hydrochloride, 500 mg.
J0696.......................... Injection, ceftriaxone 0.00668833
sodium, per 250 mg.
J0698.......................... Injection, cefotaxime 0.00014878
sodium, per gm.
J0702.......................... Injection, 0.00287709
betamethasone acetate
& betamethasone sodium
phosphate, per 3 mg.
J0704.......................... Injection, 0.00057059
betamethasone sodium
phosphate, per 4 mg.
J0735.......................... Injection, clonidine 0.00034149
hydrochloride, 1 mg.
J0800.......................... Injection, 0.00363945
corticotropin, 40
units.
J0881.......................... Injection, darbepoetin 0.15953454
alfa, 1 mcg (non-ESRD
use).
J0885.......................... Injection, epoetin 0.25136609
alpha, (for non ESRD
use), per 1000 units.
J0895.......................... Injection, deferoxamine 0.00024448
mesylate, 500 mg.
J1000.......................... Injection, depo- 0.00021013
estradiol cypionate, 5
mg.
J1020.......................... Injection, 0.00127329
methylprednisolone
acetate, 20 mg.
J1030.......................... Injection, 0.00593138
methylprednisolone
acetate, 40 mg.
J1040.......................... Injection, 0.00527803
methylprednisolone
acetate, 80 mg.
J1051.......................... Injection, 0.00006526
medroxyprogesterone
acetate, 50 mg.
J1094.......................... Injection, 0.00351268
dexamethasone acetate,
1 mg.
J1100.......................... Injection, 0.05492057
dexamethasone sodium
phosphate, 1 mg.
J1190.......................... Injection, dexrazoxane 0.00002444
hydrochloride, per 250
mg.
J1200.......................... Injection, 0.00216491
diphenhydramine hcl,
50 mg.
J1212.......................... Injection, DMSO, 0.00008475
dimethyl sulfoxide,
50%, 50 ml.
J1245.......................... Injection, 0.00383178
dipyridamole, per 10
mg.
J1250.......................... Injection, dobutamine 0.00053182
hydrochloride, per 250
mg.
J1260.......................... Injection, dolasetron 0.01737101
mesylate, 10 mg.
J1335.......................... Injection, ertapenem 0.00013263
sodium, 500 mg.
J1440.......................... Injection, filgrastim 0.00193572
(G-CSF), 300 mcg.
J1441.......................... Injection, filgrastim 0.00407388
(G-CSF), 480 mcg.
J1450.......................... Injection fluconazole, 0.00001609
200 mg.
J1580.......................... Injection, garamycin, 0.00039937
gentamicin, 80 mg.
J1600.......................... Injection, gold sodium 0.00005613
thiomalate, 50 mg.
J1626.......................... Injection, granisetron 0.01483731
hydrochloride, 100 mcg.
J1631.......................... Injection, haloperidol 0.00020702
decanoate, per 50 mg.
J1642.......................... Injection, heparin 0.06422737
sodium, (heparin lock
flush), per 10 units.
J1644.......................... Injection, heparin 0.00354562
sodium, per 1000 units.
J1645.......................... Injection, dalteparin 0.00011526
sodium, per 2500 iu.
J1650.......................... Injection, enoxaparin 0.00135618
sodium, 10 mg.
J1655.......................... Injection, tinzaparin 0.00047170
sodium, 1000 iu.
J1720.......................... Injection, 0.00013327
hydrocortisone sodium
succinate, 100 mg.
J1745.......................... Injection infliximab, 0.02762721
10 mg.
J1756.......................... Injection, iron 0.01026994
sucrose, 1 mg.
J1885.......................... Injection, ketorolac 0.00330082
tromethamine, per 15
mg.
J1940.......................... Injection, furosemide, 0.00065369
20 mg.
J1956.......................... Injection, 0.00008629
levofloxacin, 250 mg.
J2001.......................... Injection, lidocaine 0.00077528
hcl for intravenous
infusion, 10 mg.
J2010.......................... Injection, lincomycin 0.00062461
hcl, 300 mg.
J2150.......................... Injection, mannitol, 0.00029211
25% in 50 ml.
J2260.......................... Injection, milrinone 0.00004959
lactate, 5 mg.
J2300.......................... Injection, nalbuphine 0.00026341
hydrochloride, per 10
mg.
J2325.......................... Injection, nesiritide, 0.00027406
0.1 mg.
J2353.......................... Injection, octreotide, 0.00195107
depot form for
intramuscular
injection, 1 mg.
J2354.......................... Injection, octreotide, 0.00008412
non-depot subcutaneous
or intravenous
injection, 25 mcg.
J2405.......................... Injection, ondansetron 0.01373037
hydrochloride, per 1
mg.
J2430.......................... Injection, pamidronate 0.00156790
disodium, per 30 mg.
J2505.......................... Injection, 0.00065114
pegfilgrastim, 6 mg.
J2550.......................... Injection, promethazine 0.00068681
hcl, 50 mg.
J2680.......................... Injection, fluphenazine 0.00015113
decanoate, 25 mg.
J2765.......................... Injection, 0.00011134
metoclopramide hCL, 10
mg.
J2780.......................... Injection, ranitidine 0.00088550
hydrochloride, 25 mg.
J2820.......................... Injection, sargramostim 0.00217910
(GM-CSF), 50 mcg.
J2912.......................... Injection, sodium 0.00680009
chloride, 0.9%, per 2
ml.
J2916.......................... Injection, sodium 0.00061134
ferric gluconate
complex in sucrose
injection, 12.5 mg.
J2920.......................... Injection, 0.00031230
methylprednisolone
sodium succinate, 40
mg.
J2930.......................... Injection, 0.00077199
methylprednisolone
sodium succinate, 125
mg.
J2997.......................... Injection, alteplase 0.00012239
recombinant, 1 mg.
J3260.......................... Injection, tobramycin 0.00018292
sulfate, 80 mg.
J3301.......................... Injection, 0.02166537
triamcinolone
acetonide, per 10 mg.
J3302.......................... Injection, 0.00173214
triamcinolone
diacetate, per 5 mg.
J3303.......................... Injection, 0.00094603
triamcinolone
hexacetonide, per 5 mg.
J3315.......................... Injection, triptorelin 0.00000713
pamoate, 3.75 mg.
J3370.......................... Injection, vancomycin 0.00084187
hCL, 500 mg.
J3396.......................... Injection, verteporfin, 0.05438624
0.1 mg.
J3410.......................... Injection, hydroxyzine 0.00041004
hCL, 25 mg.
[[Page 9465]]
J3420.......................... Injection, vitamin B-12 0.01203050
cyanocobalamin, up to
1000 mcg.
J3475.......................... Injection, magnesium 0.00108505
sulfate, per 500 mg.
J3480.......................... Injection, potassium 0.00215709
chloride, per 2 meq.
J3487.......................... Injection, zoledronic 0.00336479
acid, 1 mg.
J7030.......................... Infusion, normal saline 0.00102834
solution, 1000 cc.
J7040.......................... Infusion, normal saline 0.00243166
solution, sterile (500
ml = 1 unit).
J7042.......................... 5% dextrose/normal 0.00049872
saline (500 ml = 1
unit).
J7050.......................... Infusion, normal saline 0.00993344
solution, 250 cc.
J7060.......................... 5% dextrose/water (500 0.00102860
ml = 1 unit).
J7070.......................... Infusion, D5W, 1000 cc. 0.00015894
J7120.......................... Ringers lactate 0.00016980
infusion, 1000 cc.
J7317.......................... Sodium hyaluronate, per 0.00191598
20 to 25 mg dose for
intra-articular
injection.
J7320.......................... Hylan G-F 20, 16 mg, 0.00149854
for intra articular
injection.
J9000.......................... Doxorubicin hCL, 10 mg. 0.00235846
J9001.......................... Doxorubicin 0.00032536
hydrochloride, all
lipid formulations, 10
mg.
J9031.......................... BCG (Intravesical) per 0.00049267
instillation.
J9040.......................... Bleomycin sulfate, 15 0.00003728
units.
J9045.......................... Carboplatin, 50 mg..... 0.00570096
J9050.......................... Carmustine, 100 mg..... 0.00000890
J9060.......................... Cisplatin, powder or 0.00095393
solution, per 10 mg.
J9062.......................... Cisplatin, 50 mg....... 0.00025430
J9065.......................... Injection, cladribine, 0.00008142
per 1 mg.
J9070.......................... Cyclophosphamide, 100 0.00062691
mg.
J9080.......................... Cyclophosphamide, 200 0.00004968
mg.
J9090.......................... Cyclophosphamide, 500 0.00008125
mg.
J9091.......................... Cyclophosphamide, 1.0 0.00005049
gram.
J9092.......................... Cyclophosphamide, 2.0 0.00000530
gram.
J9093.......................... Cyclophosphamide, 0.00092680
lyophilized, 100 mg.
J9094.......................... Cyclophosphamide, 0.00009190
lyophilized, 200 mg.
J9095.......................... Cyclophosphamide, 0.00017696
lyophilized, 500 mg.
J9096.......................... Cyclophosphamide, 0.00013977
lyophilized, 1.0 gram.
J9097.......................... Cyclophosphamide, 0.00001360
lyophilized, 2.0 gram.
J9098.......................... Cytarabine liposome, 10 0.00000817
mg.
J9100.......................... Cytarabine, 100 mg..... 0.00013010
J9110.......................... Cytarabine, 500 mg..... 0.00002076
J9130.......................... Dacarbazine, 100 mg.... 0.00009429
J9140.......................... Dacarbazine, 200 mg.... 0.00007024
J9150.......................... Daunorubicin, 10 mg.... 0.00000490
J9170.......................... Docetaxel, 20 mg....... 0.00257221
J9178.......................... Injection, epirubicin 0.00121917
hCL, 2 mg.
J9181.......................... Etoposide, 10 mg....... 0.00231466
J9182.......................... Etoposide, 100 mg...... 0.00053112
J9185.......................... Fludarabine phosphate, 0.00030647
50 mg.
J9190.......................... Fluorouracil, 500 mg... 0.00396193
J9200.......................... Floxuridine, 500 mg.... 0.00000409
J9201.......................... Gemcitabine hCL, 200 mg 0.00496182
J9202.......................... Goserelin acetate 0.00288597
implant, per 3.6 mg.
J9206.......................... Irinotecan, 20 mg...... 0.00319095
J9208.......................... Ifosfamide, 1 gm....... 0.00007892
J9209.......................... Mesna, 200 mg.......... 0.00036868
J9211.......................... Idarubicin 0.00000318
hydrochloride, 5 mg.
J9213.......................... Interferon, ALFA-2A, 0.00008082
recombinant, 3 million
units.
J9214.......................... Interferon, ALFA-2B, 0.00675198
recombinant, 1 million
units.
J9219.......................... Leuprolide acetate 0.00006526
implant, 65 mg.
J9245.......................... Injection, melphalan 0.00000159
hydrochloride, 50 mg.
J9250.......................... Methotrexate sodium, 5 0.00186700
mg.
J9260.......................... Methotrexate sodium, 50 0.00051449
mg.
J9263.......................... Injection, oxaliplatin, 0.07318565
0.5 mg.
J9265.......................... Paclitaxel, 30 mg...... 0.00556692
J9268.......................... Pentostatin, per 10 mg. 0.00000645
J9280.......................... Mitomycin, 5 mg........ 0.00004077
J9290.......................... Mitomycin, 20 mg....... 0.00003481
J9291.......................... Mitomycin, 40 mg....... 0.00006143
J9293.......................... Injection, mitoxantrone 0.00025120
hydrochloride, per 5
mg.
J9310.......................... Rituximab, 100 mg...... 0.00409565
J9320.......................... Streptozocin, 1 gm..... 0.00000673
J9340.......................... Thiotepa, 15 mg........ 0.00002452
J9350.......................... Topotecan, 4 mg........ 0.00018268
J9355.......................... Trastuzumab, 10 mg..... 0.00543348
J9360.......................... Vinblastine sulfate, 1 0.00035813
mg.
J9370.......................... Vincristine sulfate, 1 0.00019751
mg.
J9375.......................... Vincristine sulfate, 2 0.00011515
mg.
[[Page 9466]]
J9390.......................... Vinorelbine tartrate, 0.00111035
per 10 mg.
J9395.......................... Injection, fulvestrant, 0.00126670
25 mg.
J9600.......................... Porfimer sodium, 75 mg. 0.00000030
Q3025.......................... Injection, interferon 0.00078263
BETA-1A, 11 mcg for
intramuscular use.
------------------------------------------------------------------------
IV. Waiver of Proposed Rulemaking and Delay in Effective Date
We ordinarily publish a notice of proposed rulemaking in the
Federal Register to provide a period for public comment before the
provisions of a rule take effect in accordance with section 553(b) of
the Administrative Procedure Act (APA) (5 U.S.C. 553(b)). However, we
can waive the notice and comment procedures if the Secretary finds, for
good cause, that the notice and comment process is impracticable,
unnecessary or contrary to the public interest, and incorporates a
statement of the finding and the reasons therefore in the rule. We can
also waive the 30-day delay in effective date under the APA (5 U.S.C.
553(d)) when there is good cause to do so and we publish in the rule an
explanation of our good cause.
This correcting amendment addresses technical errors and omissions
made in FR Doc. 05-22160, entitled ``Medicare Program; Revisions to
Payment Policies Under the Physician Fee Schedule for Calendar Year
2006 and Certain Provisions Related to the Competitive Acquisition
Program of Outpatient Drugs and Biologicals Under Part B,'' which
appeared in the Federal Register on November 21, 2005 (70 FR 70116) and
was made effective January 1, 2006. The provisions of this final rule
with comment period have been previously subjected to notice and
comment procedures. These corrections are consistent with the
discussion and text and do not make substantive changes to the CY 2006
published rule. As such, this correcting amendment is intended to
ensure the CY 2006 final rule with comment accurately reflects the
policy adopted. Therefore, we find that undertaking further notice and
comment procedures to incorporate these corrections into the final rule
with comment is unnecessary and contrary to the public interest.
For the same reasons, we are also waiving the 30-day delay in
effective date for this correcting amendment. We believe that it is in
the public interest to ensure that the CY 2006 final rule with comment
accurately states our policy on physician fee schedule and other Part B
payment policies, and provisions related to the competitive acquisition
program of outpatient drugs and biologicals under Part B. Therefore,
delaying the effective date of these corrections beyond the January 1,
2006 effective date of the final rule with comment period would be
contrary to the public interest. In so doing, we find good cause to
waive the 30-day delay in the effective date.
(Catalog of Federal Domestic Assistance Program No. 93.774,
Medicare--Supplementary Medical Insurance Program)
Dated: February 7, 2006.
Ann C. Agnew,
Executive Secretary to the Department.
[FR Doc. 06-1711 Filed 2-23-06; 8:45 am]
BILLING CODE 4120-01-P